Radiopharmaceutical · developed by Lantheus Biosciences
[18F]PI-2620 is a radioligand labeled with fluorine-18, administered intravenously at 185 MBq for imaging. It is studied in Alzheimer disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05641688 | Phase 3 | Alzheimer Disease | Recruiting | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer Disease
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →